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Abstract—Little is known regarding fibromyalgia syndrome
(FMS) care among Operation Iraqi Freedom/Operation Enduring Freedom/Operation New Dawn (OIF/OEF/OND) Veterans.
Current recommendations include interdisciplinary, teambased combined care approaches and limited opioid use. In this
study of OIF/OEF/OND Veterans who accessed Veterans
Health Administration services between 2002 and 2012, we
hypothesized that combined care (defined as at least 4 primary
care visits/yr with visits to mental health and/or rheumatology)
versus <4 primary care visits/yr only would be associated with
lower risk of at least 2 opioid prescriptions 12 mo following an
FMS diagnosis. Using generalized linear models with a loglink, the Poisson family, and robust standard errors, we estimated risk ratios (RRs) and 95% confidence intervals (CIs).
We found that 1% of Veterans had at least 2 FMS diagnoses
(International Classification of Diseases-9th Revision-Clinical
Modification code 729.1) or at least 1 FMS diagnosis by rheumatology. Veterans with (vs without) FMS were more likely to
be female, older, Hispanic, and never/currently married. Combined primary, mental health, and rheumatology care was associated with at least 2 opioid prescriptions (RR [95% CI] for
males 2.2 [1.1–4.4] and females 2.8 [0.4–18.6]). Also, combined care was associated with at least 2 nonopioid painrelated prescriptions, a practice supported by evidence-based
clinical practice guidelines. In tandem, these results provide
mixed evidence of benefit of combined care for FMS. Future
studies of healthcare encounter characteristics, care coordination, and benefits for Veterans with FMS are needed.

Key words: Afghanistan, fibromyalgia syndrome, healthcare
setting, healthcare utilization, Iraq, OIF/OEF/OND, opioid,
primary care, PTSD, rheumatology, Veteran.

INTRODUCTION
The prevalence of fibromyalgia syndrome (FMS), a
condition characterized primarily by widespread chronic
musculoskeletal pain, has been estimated to range from

Abbreviations: CI = confidence interval, DOD = Department
of Defense, DSS = Decision Support System, FMS = fibromyalgia syndrome, HSR&D = Health Services Research and
Development Service, ICD-9-CM = International Classification of Diseases-9th Revision-Clinical Modification, OIF/
OEF/OND = Operation Iraqi Freedom/Operation Enduring
Freedom/Operation New Dawn, PTSD = posttraumatic stress
disorder, RR = risk ratio, VA = Department of Veterans
Affairs, VHA = Veterans Health Administration, VINCI = VA
Informatics Computing Infrastructure.
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1.0 to 6.0 percent in the U.S. civilian population [1–2].
Among U.S. Department of Defense (DOD) healthcare
beneficiaries aged <65 yr, a prevalence of 0.7 percent has
been reported [3]. Females and older individuals are
more likely to be diagnosed with FMS [3–5].
The prevalence and characteristics of Operation Iraqi
Freedom/Operation Enduring Freedom/Operation New
Dawn (OIF/OEF/OND) Veterans (both deployed and
nondeployed) with FMS are unknown. There is also little
research on the healthcare utilization of Veterans with
FMS and possible variations in treatment across different
healthcare providers and clinics within the Veterans
Health Administration (VHA).
Generally, evidence-based practice guidelines recommend patient-tailored approaches that may include
several nonpharmacologic and pharmacologic strategies
to reduce symptoms and improve functionality [6–9].
Briefly, nonpharmacologic strategies include patient education, graded exercise, cognitive behavioral therapy, and
complementary and alternative medicine therapies. Pharmacologic strategies include treatment with serotonin
norepinephrine reuptake inhibitors, treatment with other
nonopioid pain-related medications, and limited treatment with opioids. Guidelines also recommend interdisciplinary and integrative team-based approaches that
include regular primary care visits and possible comanagement with mental health and rheumatology specialists
[6–11]. Whether interdisciplinary, team-based combined
care approaches are associated with best practices, e.g.,
less opioid use and more use of nonopioid pain-related
medication, is unknown.
To support the implementation of evidence-based
management of FMS in the VHA, we examined characteristics and healthcare utilization of OIF/OEF/OND Veterans with FMS. Our specific objectives were to describe
sociodemographic and military characteristics of Veterans with FMS and to identify primary clinical sites of
FMS diagnoses. Our secondary objective was to test the
hypothesis that Veterans managed by an interdisciplinary,
team-based approach of care for FMS (vs Veterans who
are not) are less likely to be prescribed opioid medications and more likely to be prescribed nonopioid painrelated medications in the 12 mo following a FMS diagnosis. We defined a proxy variable for an interdisciplinary, team-based approach of care for FMS as combined
utilization of regular primary care with mental health
and/or rheumatology care within 12 mo of a diagnosis.

METHODS
Study Setting
Our cross-sectional study included Veterans from the
national OIF/OEF/OND Roster file that is provided to the
Department of Veterans Affairs (VA) Central Office
Environmental Epidemiology Service by the Defense
Manpower Data Center. The OIF/OEF/OND Roster
includes Veterans who are a subset of military discharges
identified as having VHA healthcare utilization. The
OIF/OEF/OND Roster file was merged with data in the
VA Informatics Computing Infrastructure (VINCI) [12].
These data include basic demographic files, clinical data,
and all national inpatient and outpatient services provided to VHA healthcare users. Data for outpatient services in VHA include 6-digit Decision Support System
(DSS) identifiers. These DSS identifiers are used to characterize outpatient clinic settings and are the single and
critical designation by which VHA defines outpatient
clinical work units for costing purposes [13]. The first
3 digits of the DSS identifier, or primary “stop code,”
designate the main clinical group responsible for patient
care. The last 3 digits of the DSS identifier, or secondary
“stop code,” can be used by a VHA medical facility to
further specify the main clinical group, for example, to
specify the type of service provided or type of provider/
team that administered the care. The list of nationally
standardized codes is reviewed and updated at least annually by VHA’s National Stop Code Council, and lists of
stop code changes and active stop codes as well as a current stop code instructional guide are posted on the DSS
Identifier Web page.
Participants
The OIF/OEF/OND Roster included 647,288 male
and 90,819 female Veterans who accessed VHA from fiscal years 2002–2012. Of these, we identified 15,420 male
and 4,179 female Veterans who had ≥1 outpatient diagnosis of FMS by the International Classification of Diseases9th Revision-Clinical Modification (ICD-9-CM) code
729.1: myalgia and myositis, unspecified. Researchers
have cautioned that a single ICD-9-CM FMS diagnosis or
diagnoses in nonrheumatology settings may have limited
specificity to identify true FMS cases [1,14–15]. To
improve the specificity of our FMS case definition and to
be consistent with prior research of VHA administrative
data [16], we only included Veterans who received
≥1 FMS diagnosis in a rheumatology specialty care setting
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(identified by corresponding clinic stop code of 314) or
≥2 FMS diagnoses on separate dates within 12 mo, regardless of outpatient care setting. There were 5,963 male and
2,245 female Veterans who met our FMS case definition.
Outpatient Settings of Index FMS Diagnoses
We defined the date of index FMS diagnosis to be the
date of whichever came first: (1) the date of diagnosis in
a rheumatology specialty care setting or (2) the first date
of ≥2 FMS diagnoses (on separate dates) within 12 mo.
We used the term “index FMS date” to distinguish our
analysis from one that examines incident FMS, since we
did not determine whether Veterans were free of FMS
before the index date. In addition to rheumatology, we
examined the top 10 primary stop codes where an FMS
diagnosis was coded, stratified by male and female Veterans, on the date of index FMS diagnosis.
Exposure Definitions: Utilization of Primary Care
and Mental Health and Rheumatology Specialty Care
We classified primary care encounters to be any VHA
visits with a primary stop code of 342, 348, 350, or 323,
excluding secondary stop code 135. We classified
encounters by mental health to be any VHA visits with a
primary stop code of 502–524, 527–599, or 725–731.
Rheumatology specialty care visits were classified by any
VHA visits with a primary stop code of 314. Multiple visits for categories of primary care, mental health, or rheumatology were counted only if they occurred on separate
dates. Follow-up by primary care, mental health, and/or
rheumatology was examined 12 mo after the index FMS
date. In the absence of an explicitly stated definition of
regular primary care in the current VA/DOD Clinical
Practice Guideline for the Management of Chronic Multisymptom Illness [17], we used an empirically derived definition for regular primary care as greater than or equal to
the median number of visits over 12 mo of follow-up
from the index date of FMS diagnosis.
Outcome Definitions: Pharmacologic Outcomes
We examined the number of uniquely dated prescriptions generated for opioid and nonopioid pain-related
medications during the 12 mo after the index FMS date.
A complete list of opioid and nonopioid pain-related
medications included in our analyses is in Appendix 1
(available online only). We dichotomized users of opioid
and nonopioid pain-related medications separately using
a cutoff of 2 uniquely dated prescriptions in the 12 mo
after the index FMS date.

Definitions of Potential Confounding Variables
Sociodemographic and Military Service Characteristics
We examined sociodemographic characteristics
including age, race, marital status, and education. We
reported age at date of first VHA encounter and age at
index FMS date. We also examined factors related to Veterans’ military service component (Active Duty vs
reserve), rank, and branch of service.
Mental Health Comorbidities
Because mental health diagnoses of anxiety, posttraumatic stress disorder (PTSD), and depression have
been associated with FMS and are risk factors for opioid
prescriptions [18], we examined these mental health
diagnoses associated with outpatient encounters during
the 12 mo following the index FMS date. We used ICD9-CM diagnostic codes 300.00–300.09, 300.20–300.29,
and 300.3 to categorize anxiety; code 309.81 to categorize PTSD; and codes 296.20–296.25, 296.30–296.36,
300.4, and 311 to categorize depression diagnoses
according to a previously published study of mental
health diagnoses in the OIF/OEF/OND Veteran population [19]. These represent a cluster of mood and anxiety
disorders that most prior FMS research has focused on
[20–21], but it is not an exhaustive list. Others include
conversion and bipolar disorder, which are not the focus
of this current study [22–23].
Charlson Comorbidity Index
The Charlson Comorbidity Index is a validated measure of the number and severity of coexisting diagnoses.
For each Veteran with FMS, we calculated the Charlson
Comorbidity Index [12] using ICD-9-CM diagnostic
codes related to inpatient and outpatient encounters during the 12 mo following the index FMS date [24].
Statistical Analysis
We examined frequency distributions of sociodemographic and military service characteristics among Veterans who met our FMS case definition and Veterans who
had no FMS diagnoses from fiscal years 2002–2012,
stratified by sex. We used the Pearson chi-square test to
examine statistically significant differences in the distribution of these characteristics.
We examined associations between combined utilization of regular primary care with mental health and/or
rheumatology care as a proxy for an interdisciplinary,
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team-based approach (vs only primary care utilization)
and the risk of 2 opioid or 2 nonopioid pain-related
prescriptions in the 12 mo following the index FMS diagnosis. We restricted our analysis to Veterans with 1 primary care visit during the 12 mo of follow-up to avoid
including Veterans who may have sought care only outside of the VHA. To examine these associations, we fit
generalized linear models with a log-link, Poisson family
(a log-Poisson regression model), and robust standard
errors to estimate risk ratios (RRs) and 95 percent confidence intervals (CIs). The log-Poisson regression model
with robust standard errors allows estimation of RRs for
prospective studies with binary outcome data [25].
The following potential confounding variables were
identified a priori and were included in all adjusted models, including Model 1: number of anxiety, PTSD, and
depression diagnoses during the 12 mo after index FMS
date and nonreferent indicator variables (i.e., dummy
variables that excluded the reference category) for each
mental health disorder (1, 2, and 3 diagnoses). We also
adjusted for the Charlson Comorbidity Index
(2 nonreferent indicator variables: 1 and 2). We used
indicator variables to allow flexibility for fitting potential
nonlinear associations. In Model 2, we additionally
adjusted for sociodemographic and military characteristic
variables: age at index FMS date (2 nonreferent indicator
variables: >30–40 and >40); white, non-Hispanic race/
ethnicity; married marital status; and greater than high
school education as well as Active Duty status and
branch of service (4 nonreferent indicator variables: Air
Force, Navy, Marines Corps, and Coast Guard).
There have been temporal changes in the “VA/DOD
Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain” [26–27]. These may have
resulted in changes to FMS management, including prescribing practices of opioid and nonopioid pain-related
medications. We explored whether our results were sensitive to the adjustment for the year of index FMS diagnosis by including 10 nonreferent indicator variables for
calendar years 2002–2011 [3,28]. We also explored
whether adjustment for the index FMS setting (whether
in a rheumatology setting) materially altered our results.
Researchers have advised that for mental health diagnoses determined by ICD-9-CM codes, those who only
have one diagnosis code may not truly have the mental
health diagnosis [16]. To address this potential limitation,
we also explored whether results for Model 1 were sensitive to recoding of individuals who had only one ICD-9-

CM code corresponding to anxiety, PTSD, or depression
as having no diagnosis.
All p-values were two-sided and defined to be significant at p < 0.01. All analyses were conducted using Stata
software (version 12.1, StataCorp; College Station, Texas).
RESULTS
Prevalence and Characteristics of Veterans with FMS
The prevalence of FMS was higher among female than
male Veterans. There were 5,963 (0.9%) male and 2,245
(2.5%) female Veterans, or 1 percent of male and female
Veterans combined, with prevalent FMS according to our
case definition among OIF/OEF/OND Veterans who had
≥1 VHA encounter from fiscal years 2002–2012. Compared with the 631,868 male and 86,640 female Veterans
who did not have a FMS diagnosis during the 10 yr study
period, Veterans with FMS were older, more likely to be
Hispanic, and never or currently married, regardless of sex
(Table 1). Females with FMS were more likely to have
attained more than a high school education and to have
served in the Air Force than females without FMS. Males
with FMS were more likely to have served in the Army
than males without FMS.
Outpatient Settings of Index FMS Diagnosis
Over a quarter of FMS diagnoses were documented
in a primary care setting (24% for male and 29% for
female Veterans) (Table 2). The other top five settings
were similar for FMS diagnoses across male and female
Veterans, including chiropractic care, physical medicine
and rehabilitation, and rheumatology/arthritis specialty
care settings. Eight percent of female Veterans with FMS
received an index diagnosis in women’s health-related
specialty clinic settings. A higher proportion of male
(11%) versus female (6%) Veterans received their index
FMS diagnosis in a pain specialty clinic.
Utilization of Primary Care and Mental Health and
Rheumatology Specialty Care
Among 4,855 male and 1,786 female Veterans with
at least 12 mo of follow-up after their FMS index date,
most male (n = 4,441 [91%]) and female (n = 1,526
[85%]) Veterans had ≥1 primary care encounter. Also,
most male (n = 3,437 [71%]) and female (n = 1,299
[73%]) Veterans had ≥1 mental health encounter. Fewer
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Table 1.
Sociodemographic and military service characteristics among Veterans, returned from Iraq and Afghanistan, who accessed Veterans Health
Administration (VHA) care during fiscal years 2002–2012. Data presented as n (%).
Females With FMS
Females Without FMS
Males With FMS
Males Without FMS
Characteristic
(n = 631,868)
(n = 2,245)
(n = 86,640)
(n = 5,963)
Age Group at First VHA Encounter (yr)*
18–30
2,734 (45.8)
343,440 (54.4)†
962 (42.9)
52,194 (60.2)†
>30–40
1,587 (26.6)
140,451 (22.2)
636 (28.3)
18,609 (21.5)
>40–50
1,295 (21.7)
115,101 (18.2)
519 (23.1)
12,677 (14.6)
>50–60
339 (5.7)
30,442 (4.8)
113 (5.0)
3,021 (3.5)
>60–75
7 (0.1)
2,262 (0.4)
6 (0.3)
136 (0.2)
Race*
White
2,915 (48.9)
362,543 (57.4)†
776 (34.6)
38,790 (44.8)†
Black
555 (9.3)
70,817 (11.2)
449 (20.0)
18,963 (21.9)
Hispanic
767 (12.9)
583 (0.1)
235 (10.5)
55 (0.1)
Other
261 (4.4)
22,595 (3.6)
166 (7.4)
3,452 (4.0)
Marital Status*
Never Married
2,427 (40.7)
199,276 (31.5)†
1,023 (45.6)
31,332 (36.2)†
Married
3,215 (53.9)
278,436 (44.1)
898 (40.0)
25,741 (29.7)
Divorced/Separated/Widowed
318 (5.3)
91,304 (14.4)
319 (14.2)
19,462 (22.5)
Education*
≤High School
4,596 (77.1)
494,116 (78.2)
1,514 (67.4)
62,434 (72.1)†
>High School
1,285 (21.6)
129,833 (20.5)
700 (31.2)
22,983 (26.5)
Component
Active Duty
3,003 (50.4)
349,351 (55.3)
1,232 (54.9)
48,615 (56.1)
National Guard/Reserve
2,960 (49.6)
282,517 (44.7)
1,013 (45.1)
38,025 (43.9)
Rank‡
Enlisted
5,638 (94.6)
581,543 (92.0)†
2,055 (91.5)
78,397 (90.5)
Officer
254 (4.3)
43,720 (6.9)
169 (7.5)
7,726 (8.9)
Branch of Service‡
Army
4,088 (68.6)
399,110 (63.2)†
1,443 (64.3)
55,392 (63.9)†
Air Force
585 (9.8)
63,726 (10.1)
452 (20.1)
14,325 (16.5)
Navy
552 (9.3)
74,282 (11.8)
301 (13.4)
13,408 (15.5)
Marine Corps
733 (12.3)
94,183 (14.9)
47 (2.1)
3,469 (4.0)
*Some
†

values are “missing” or “unknown” for these characteristics.
Some values for these characteristics are “other.”
‡
Chi-square test, comparison across FMS status (p < 0.01).
FMS = fibromyalgia syndrome.

male (n = 733 [15%]) and female (n = 516 [29%]) Veterans had ≥1 follow-up rheumatology specialty care visit.
For the 4,441 male and 1,526 female Veterans who
had ≥1 primary care visit during the 12 mo following
their index FMS diagnosis date, the median (range) of
primary care encounters for male and female Veterans
was 4 (1–54) and 4 (1–61) visits, respectively. The
median (range) of mental health encounters for male and
female Veterans was 5 (0–231) and 6 (0–183) visits,
respectively. For rheumatology care encounters 12 mo
following index FMS diagnosis date, the median (range)
for male and female Veterans was 0 (0–13) and 0 (0–15)
visits, respectively. Most Veterans (~80%) received a

combination of primary care and mental health or a combination of primary care and rheumatology care (Table
3). A higher proportion of female (n = 357 [23%]) than
male (n = 531 [12%]) Veterans received a combination of
care from all three settings.
Associations of Combined Primary Care with Mental
Health and/or Rheumatology Utilization and PainRelated Medication Prescriptions
There were 1,830 (41%) males and 589 (39%) females
who received ≥1 opioid prescription among Veterans with
≥1 primary care visit during the 12 mo following their
index FMS diagnosis date. Most Veterans received
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Table 2.
Top 10 fibromyalgia syndrome (FMS) outpatient care settings corresponding to index FMS diagnosis, restricted to Veterans who
unique stop code.*
Male Veterans (n = 5,692)
Female Veterans (n = 2,150)
Top 10 Primary Stop Codes
n (%)
Top 10 Primary Stop Codes
Primary Care: 342, 348, 350, or 323
1,367 (24.0)
Primary Care: 342, 348, 350, or 323
(excluding secondary stop code 135)
(excluding secondary stop code 135)
Chiropractic Care: 436
904 (15.9)
Rheumatology/Arthritis: 314
Physical Medicine & Rehabilitation: 201
829 (14.6)
Physical Medicine & Rehabilitation: 201
Pain Clinic: 420
595 (10.5)
Women’s Health Clinic: 322, 339, 404, 426, 525, or
704
Rheumatology/Arthritis: 314
461 (8.1)
Chiropractic Care: 436
Polytrauma/Traumatic Brain Injury/Speech
315 (5.5)
Pain Clinic: 420
Pathology: 197 or 219
Physical Therapy: 205
281 (4.9)
Polytrauma/Traumatic Brain Injury/Speech
Pathology: 197 or 219
Complementary Alternative Medicine: 159
118 (2.1)
Physical Therapy: 205
Laboratory: 108
79 (1.4)
Mental Health: 502–524, 527–599, or 725–731
Neurology: 106, 126–128, 293, 315, 325, 335, 345, or
76 (1.3)
Neurology: 106, 126–128, 293, 315, 325, 335, 345, or
346
346
Other Outpatient Setting
462 (8.1)
Other Outpatient Setting

only had one
n (%)
632 (29.4)
300 (14.0)
283 (13.2)
173 (8.0)
155 (7.2)
131 (6.1)
69 (3.2)
63 (2.9)
35 (1.6)
31 (1.4)
166 (7.7)

*13

males and 2 females were missing stop code associated with FMS index date/diagnosis; 258 males and 93 females had ≥2 unique stop code combinations associated with FMS index date/diagnosis.

Table 3.
Primary care, mental health, and rheumatology utilization 12 mo after index fibromyalgia syndrome date among Veterans who had at ≥1 primary
care follow-up visit.*

Care Setting
Primary Care Only (n)
<4 Visits (%), reference category
4 Visits (%)
Primary Care & Mental Health, No Rheumatology (n)
<4 Primary Care Visits (%)
4 Primary Care Visits (%)
Primary Care & Rheumatology, No Mental Health (n)
<4 Primary Care Visits (%)
4 Primary Care Visits (%)
Combined Primary Care, Mental Health, & Rheumatology (n)
<4 Primary Care Visits (%)
4 Primary Care Visits (%)

Male Veterans
(n = 4,441)
1,055 (23.8)
695 (15.6)
360 (8.1)
2,706 (60.9)
1,135 (25.6)
1,571 (35.4)
149 (3.4)
88 (2.0)
61 (1.4)
531 (12.0)
186 (4.2)
345 (7.8)

Female Veterans
(n = 1,526)
288 (18.9)
173 (11.3)
115 (7.5)
787 (51.6)
336 (22.0)
451 (30.0)
94 (6.2)
52 (3.4)
42 (2.8)
357 (23.4)
124 (8.1)
233 (15.3)

*1,108

males and 459 females had <12 mo of follow-up, and 414 males and 260 females had no primary care visits; multiple visits can occur on same day only if
visits are in different settings.

≥1 nonopioid pain-related prescription: 3,017 (68%) males
and 1,124 (74%) females. The median (range) of opioid
prescriptions for male and female Veterans was 3 (1–42)
and 2 (1–26), respectively. The median (range) of nonopioid pain-related prescriptions for male and female Veterans was 2 (1–20) and 2 (1–21), respectively.
Contrary to our primary hypothesis, we found that
compared with <4 primary care visits (i.e., less than regu-

lar primary care), combined regular primary care, mental
health, and rheumatology utilization was associated with
2 opioid prescriptions: RRs and 95 percent CIs for male
and female Veterans were 2.22 (1.13–4.39) and 2.79
(0.42–18.62), respectively, for the fully adjusted model
(Model 2, Tables 4–5).
Supporting our secondary hypothesis, we did find
evidence that compared with Veterans who received less
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Table 4.
Associations of combined regular primary care and mental health and/or rheumatology utilization and pain-related medication prescriptions
(opioid or nonopioid) 12 mo following index fibromyalgia syndrome (FMS) diagnosis date among male Veterans (n = 4,441).

Model Variable
No. at Risk
No. with 2 Opioid Rx
RR (95% CI)
Unadjusted
Model 1*
Model 2†
No. with 2 Nonopioid Rx
RR (95% CI)
Unadjusted
Model 1*
Model 2†

<4 PC
Visits Only
695
75

4 PC
Visits Only
360
78

4 PC
Visits & MH
1,571
662

4 PC
Visits & RH
61
9

4 PC Visits,
MH & RH
345
151

1.0 (reference)
1.0 (reference)
1.0 (reference)
59

2.01 (1.50–2.68)
1.40 (0.71–2.75)
2.02 (0.89–4.57)
67

3.90 (3.13–4.87)
1.77 (1.06–2.98)
2.20 (1.13–4.29)
1,001

1.37 (0.72–2.59)
0.97 (0.26–3.58)
1.04 (0.17–6.45)
20

4.06 (3.17–5.18)
1.82 (1.07–3.09)
2.22 (1.13–4.39)
245

1.0 (reference)
1.0 (reference)
1.0 (reference)

2.19 (1.58–3.04)
2.60 (1.14–5.91)
3.42 (0.98–11.88)

7.51 (5.86–9.61)
4.50 (2.21–9.15)
6.99 (2.32–21.09)

3.86 (2.50–5.96)
2.37 (0.71–7.89)
2.02 (0.27–15.11)

8.37 (6.49–10.78)
4.92 (2.41–10.05)
7.79 (2.57–23.57)

*Model 1 is adjusted for no. anxiety diagnoses (1, 2, 3), no. posttraumatic stress disorder diagnoses (1, 2, 3), no. depression diagnoses (1, 2, 3), and Charlson
Comorbidity Index (1, 2); each value is included as an indicator variable.
†Model 2 adjusts for same variables in Model 1 in addition to sociodemographic variables: age at FMS index date (2 indicator variables: >30–40, >40), white nonHispanic race/ethnicity, married marital status, greater than high school education, and military characteristics: Active Duty, branch of service (4 indicator variables:
Air Force, Navy, Marine Corps, Coast Guard).
CI = confidence interval, MH = mental health, No. = number, PC = primary care, RH = rheumatology, RR = risk ratio, Rx = prescription.

Table 5.
Associations of combined primary care and mental health and/or rheumatology utilization and pain-related medication prescriptions (opioid or
nonopioid) 12 mo following index fibromyalgia syndrome (FMS) diagnosis date among female Veterans (n = 1,526).

Model Variable
No. at Risk
No. with 2 Opioid Rx
RR (95% CI)
Unadjusted
Model 1*
Model 2†
No. with 2 Nonopioid Rx
RR (95% CI)
Unadjusted
Model 1*
Model 2†

<4 PC
Visits Only
173
14

4 PC
Visits Only
115
21

4 PC
Visits & MH
451
155

4 PC
Visits & RH
42
10

4 PC Visits,
MH & RH
233
78

1.0 (reference)
1.0 (reference)
1.0 (reference)
24

2.26 (1.20–4.25)
2.59 (0.28–23.57)
2.12 (0.24–18.55)
27

4.25 (2.53–7.13)
3.95 (0.61–25.67)
2.95 (0.45–19.30)
300

2.94 (1.41–6.16)
—‡
—‡
16

4.14 (2.43–7.06)
3.89 (0.60–25.50)
2.79 (0.42–18.62)
169

1.0 (reference)
1.0 (reference)
1.0 (reference)

1.69 (1.03–2.78)
1.65 (0.44–6.14)
1.03 (0.26–4.12)

4.79 (3.29–6.99)
3.15 (1.14–8.77)
2.19 (0.82–5.87)

2.75 (1.61–4.69)
1.91 (0.50–7.36)
0.85 (0.21–3.45)

5.23 (3.58–7.64)
3.38 (1.22–9.41)
2.32 (0.87–6.21)

*Model 1 is adjusted for no. anxiety diagnoses (1, 2, 3), no. posttraumatic stress disorder diagnoses (1, 2, 3), no. depression diagnoses (1, 2, 3), and Charlson
Comorbidity Index (1, 2); each value is included as an indicator variable.
†
Model 2 adjusts for same variables in Model 1 in addition to sociodemographic variables: age at FMS index date (2 indicator variables: >30–40, >40), white nonHispanic race/ethnicity, married marital status, greater than high school education, and military characteristics: Active Duty, branch of service (4 indicator variables:
Air Force, Navy, Marine Corps, Coast Guard).
‡
Too few events limited risk estimation.
CI = confidence interval, MH = mental health, No. = number, PC = primary care, RH = rheumatology, RR = risk ratio, Rx = prescription.

than regular primary care (<4 primary care visits in the 12
mo after index FMS date), combined regular primary
care, mental health, and rheumatology utilization was
associated with 2 nonopioid pain-related prescriptions:
RRs and 95 percent CIs for male and female Veterans
were 7.79 (2.57–23.57) and 2.32 (0.87–6.21), respectively, for the fully adjusted model (Model 2, Tables 4–5).

These results were not materially altered when we
further adjusted for the year of index FMS diagnosis and
whether the index diagnosis was in a rheumatology setting
(Appendix 2, available online only). Also, our results
were robust to recoding of individuals with one diagnosis
of anxiety, PTSD, or depression to having no diagnosis
for these conditions.
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DISCUSSION
To the best of our knowledge, this is the first study to
report the prevalence and related sociodemographic and
military characteristics of FMS among national OIF/OEF/
OND Veterans. We report a 10 yr FMS prevalence of
0.9 percent among males and 2.4 percent among females
who accessed the VHA. Over a quarter of FMS diagnoses
were documented in a primary care setting. Compared
with Veterans without FMS, Veterans with FMS were
more likely to be female, older, never/currently married,
and to have served in the Army (males) or Air Force
(females). One year following index FMS diagnosis, most
Veterans sought a combination of primary care and mental
health and/or rheumatology. Contrary to our primary
hypothesis, Veterans with FMS with regular primary care
visits combined with mental health and rheumatology visits were more likely to be prescribed 2 opioids during
the 12 mo following index FMS diagnosis. Combined
care was also associated with 2 nonopioid pain-related
prescriptions.
The prevalence of FMS in our study of OIF/OEF/OND
Veterans was within the range reported in studies of civilian [1] and military populations [3]. Researchers have
reported that among Gulf war Veterans, deployment (versus nondeployment) may be associated with a doubling of
the risk of FMS (odds ratio 2.32 [95% CI: 1.02–5.27])
[29]. The present study did not examine the association
between deployment and FMS diagnosis. Other characteristics that we found to be related to FMS diagnoses were
consistent with prior studies, including older age and
female sex [1,3,5,14]. The FMS-female sex association is
worth noting because women continue to be one of the
fastest growing subsets of VHA users [30]. We are
unaware of prior studies that report a higher prevalence of
FMS among those of Hispanic ethnicity, though there are
limited investigations of race/ethnicity and FMS. Studies
of chronic pain in general support that Hispanic and African American race/ethnicities are at greater risk of experiencing pain, but it is unclear that these differences remain
after controlling for other confounding variables [31]. If
our findings are replicated, they may provide evidence for
potential disparities in the experience of FMS and FMS
management among ethnic minorities. Identification of
disparities in pain and pain management has been highlighted as an area of needed future research in the Institute
of Medicine’s “Relieving Pain in America: A Blueprint for

Transforming Prevention, Care, Education and Research”
[32].
Consistent with a prior non-VHA study of FMS,
FMS diagnoses were most common in primary care [15].
In our study of the VHA, other predominant nonrheumatology clinical settings of FMS diagnoses included chiropractic care, physical medicine and rehabilitation, and
pain clinics. Also, among females, women’s healthrelated clinics were one of the top five settings of FMS
diagnoses. Since most diagnoses of FMS occur outside
the rheumatology setting, it may be important to ensure
that clinicians in these settings are made aware of and
trained in the latest evidence-based practice guidelines
for diagnosing and managing FMS and that procedures
are in place for timely referrals to rheumatology, especially if a diagnosis is elusive [10]. Some experts recommend that rheumatologists train primary care colleagues
on the recognition of FMS [33].
Investigators have demonstrated that patients with
FMS in both civilian and military populations have
higher utilization of healthcare. Berger et al. reported that
compared with civilians without FMS, those with FMS
had twice as many outpatient and four times as many
emergency room visits over 12 mo [14]. Other investigators have reported that utilization of healthcare is higher
for FMS than other chronic medically unexplained symptoms among military personnel, including irritable bowel
syndrome and chronic fatigue syndrome [3]. Therefore, it
may not be surprising that in the present study most Veterans sought a combination of primary care and mental
health and/or rheumatology specialty care 12 mo following their index FMS diagnosis; this was especially evident for combined primary care with mental health.
Whether utilization of combined care in our study is
a reflection of a guideline-recommended, interdisciplinary, team-based approach; comorbid diagnoses; and/or
challenges related to identifying and managing FMS is
uncertain. On the one hand, FMS is known to be associated with a number of comorbid conditions; seven conditions were reported by investigators of a civilian
population-based study, including depression, anxiety,
headache, irritable bowel syndrome, chronic fatigue syndrome, systemic lupus erythematous, and rheumatoid
arthritis [5]. Each of these conditions was 2 to 7 times
more likely to be present in patients with FMS than
patients without FMS. PTSD is another condition that is
often comorbid with FMS and highly prevalent in the
OIF/OEF/OND Veteran population [11,34–37]. While we
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did not examine all reported comorbid conditions of
FMS, we did examine mental health-related conditions.
The prevalence of ≥1 diagnosis for anxiety, PTSD, and
depression 12 mo following index FMS date was 21.5,
51.0, and 21.0 percent, respectively. Restricting to individuals with ≥2 diagnoses reduced these prevalence estimates by 5 percent. The combined utilization of primary
care with mental health among Veterans in our study may
be expected given the high prevalence of mental health
conditions. On the other hand, combined care may be a
reflection of high healthcare utilization overall, which
may indicate complexity of the patients, poor coordination of care, and challenges related to diagnosing FMS
[7,10,38]. We did not examine overall healthcare utilization of Veterans seeking combined care (vs those with
primary care visits only), nor could we examine the reasons for follow-up utilization. As a result, it is unclear
whether combined utilization represents recommended
interdisciplinary, team-based approaches for managing
FMS; higher utilization of services to independently
address the multiple comorbid conditions [11]; or perhaps overutilization of VHA care. Lastly we note that
stop codes, for mental health services in particular, likely
reflect various levels of interdisciplinary and integrative
treatment, which the current study could not examine.
We sought empiric evidence to support the clinical
practice guideline recommendations that combined care
is associated with best practices, i.e., less opioid use and
more use of nonopioid pain-related medication. Contrary
to our first hypothesis, results support associations of
combined care with a higher risk of receiving 2 opioid
prescriptions. We note that this finding is correlational,
and we are unable to infer a direction of causality. Bearing this in mind, there are several potential explanations
for our findings. The association between indicators of
combined care and opioid therapy is consistent with clinical practice guidelines for opioid therapy [28]. Also, it
may be that patients who receive opioid therapy are those
with more complex, severe, and treatment-refractory
conditions. Thus, the evidence for an association between
combined care and opioid therapy may be consistent with
a prior escalation of care in the service of attempting to
better manage pain.
Our study robustly supports the hypothesis that Veterans with utilization of mental health and rheumatology
in addition to regular primary care are more likely to be
prescribed 2 nonopioid pain-related medications (guideline-adherent practice). For instance, when we explored a

change in our reference category to “only regular primary
care” users (rather than less than “only regular primary
care” users), associations between combined regular primary care, mental health, and rheumatology utilization
and 2 nonopioid pain-related medications remained statistically significant (Appendix 2, Model 2). In contrast,
there is less evidence supporting that Veterans with combined care are more likely to be prescribed opioids (not
consistent with guideline recommendations). When we
explored a change in our reference category to “only regular primary care” users, the association of combined
care and opioid use was no longer statistically significant.
Thus, it may be that regular or greater primary care utilization (compared with less than regular primary care utilization) and not combined care per se is associated with
higher likelihood of being prescribed opioids, perhaps
due to other indications for opioid prescription and the
necessary, regular encounters to responsibly manage the
opioid use.
LIMITATIONS
As with all studies that rely on administrative data,
there is the potential for misclassification of FMS. Since
we were interested in focusing our analyses on Veterans
with true diagnoses of FMS, we required that Veterans
have ≥2 ICD-9-CM diagnoses of FMS in a 12 mo period
or ≥1 diagnosis in a rheumatology specialty care setting.
Although this definition has not been examined for validity in the OIF/OEF/OND Veteran population, similar definitions have been used in studies of military personnel
and our prevalence estimates in male and female Veterans are similar to those reported previously [3]. Another
weakness was that we were unable to determine the incident date of FMS diagnosis, which precluded analyses of
causal relationships and limited our interpretation of temporal relationships. We relied on an index FMS diagnosis
date, the first documentation of FMS in VHA diagnosis
codes over the study period.
Interpretation of the results related to the examination of healthcare utilization and treatment during the
12 mo following the index FMS date should be made in
the context of several potential limitations. These include
use of combined utilization of regular primary care with
mental health and/or rheumatology care as a proxy for an
interdisciplinary, team-based approach to FMS care. We
are uncertain whether this proxy is appropriate or
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whether it is a reflection of escalated care utilization
driven by patient need that is not interdisciplinary or integrative in nature. Since we did not examine reasons
(including diagnoses) related to follow-up primary care,
mental health, and rheumatology visits, we cannot make
strong assertions regarding the potential benefit or harm
of combined care for FMS. Second, we did not account
for the potential variability in the specific knowledge or
clinical expertise of the providers, which may be a valuable area for future research. Third, since we were unable
to identify an explicit definition of regular primary care
for FMS in the current “VA/DOD Clinical Practice
Guideline for the Management of Chronic Multisymptom
Illness” [17], we used the median number of visits in
12 mo, 4 primary care visits, to define “regular primary
care,” which may not be clinically relevant or may have
limited generalizability. We note that our definition of
“regular primary care” as 4 primary care visits/yr is
consistent with some previous studies of management of
somatoform disorders [39]. Fourth, although we
attempted to control for potential confounding variables,
there may be residual confounding, which if present
would bias our estimates of risk. To ensure that we had
adequate power to estimate RRs, we used the medians
(among Veterans with medication use) for analyses of
pain-related medication associations. However, especially for the analyses of opioids, a more clinically relevant outcome may be chronic use. Because we did not
have details on dose or longitudinal duration of continued
or intermittent treatment, we were unable to examine
chronic use. Also, we used prescription history as noted
in the electronic medical record as an indicator for medication use; we did not determine whether patients actually consumed their medications or how adherent they
were to prescription instructions. We were unable to
examine the clinical indication for the medication prescriptions. For example, some of the nonopioid painrelated medications, antidepressants and gabapentinoids,
in particular, may have been prescribed for the management of nonpain medical and mental health comorbidities
that are common among patients with FMS. There may
have been losses to follow-up, which could introduce
selection bias, although we attempted to address this by
including only Veterans with ≥1 primary care visit
through the VHA during the 12 mo following FMS index
date. Future investigations are needed to examine other
guideline-recommended treatments for FMS, including
patient education, graded exercise, cognitive behavioral

therapy, and complementary and alternative medicine
therapies.
CONCLUSIONS
Our present study extends the current scope of
research on FMS to include OIF/OEF/OND Veterans
who access VHA. Our study confirmed several previously identified risk factors for FMS and identified
potential new risk factors (e.g., Hispanic ethnicity) that
warrant further investigation. Contrary to our hypothesis,
Veterans with FMS who utilized regular primary care,
mental health, and rheumatology (combined care) were
more likely to be prescribed opioids. However, closer
examination suggests that regular primary care (relative
to less than regular primary care) is driving the association. Combined care was also associated with 2 nonopioid pain-related prescriptions; unlike the findings for
opioid medications, results were not materially altered in
our sensitivity and exploratory analyses. Future studies
are needed to more closely examine associations of interdisciplinary, team-based approaches to FMS care, overall
VHA utilization, and recommendations for FMS treatment. Such studies can support the implementation of
evidence-based management of FMS in VHA.
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